---
layout: cv
title: David Miller's CV
---
# David Miller
PhD Candidate, University College London

Division of Biosciences & UCL Centre for Artificial Intelligence<br/>
University College London<br/>
Gower Street, London WC1E 6BT, UK<br/>

<a href="david.miller.20@ucl.ac.uk">david.miller.20@ucl.ac.uk</a>

<div id="webaddress">
  <a href="https://dmmiller597.github.io"><i class="fa-solid fa-house"></i> dmmiller597.github.io</a> - 
  <a href="https://github.com/dmmiller597"><i class="fa-brands fa-github"></i> dmmiller597</a> - 
  <a href="[https://www.linkedin.com/in/david-miller-921715126/](https://www.linkedin.com/in/david-miller-921715126/)"><i class="fa-brands fa-linkedin"></i> linkedin</a>
</div>

## Education

`2022-2026`
**Ph.D., Computational Biology**, *University College London*, London, UK.
- Focus on developing deep learning methods for functional annotation of proteins to inform protein design

`2021`
**M.Sc., Health Data Science**, *University College London*, London, UK.

`2020`
**Pre-Medicine/Pre-Medical Studies**, *University of Pennsylvania*, Philadelphia, PA, USA.

`2016`
**B.A., Physics**, *Bowdoin College*, Brunswick, ME, USA.

## Experience

`Sep 2023 - Jan 2024`
**Computational Biology Intern**, *VantAI*
- Developed deep learning methods to predict degradation motifs in protein sequences using protein languge models.

`Jan 2023 - May 2023`
**Visiting Scientist**, *The Francis Crick Institute*
Worked on RNA Timestamps, a novel method to estimate the age of sinlge molecule RNA from sequencing data.

`Nov 2021 - Jan 2023`
**Researcher**, *UCL*, Computational Medicine Lab
- Led projects in HERMES, a large-scale genomics consoritum for discovering novel drug targets in Heart Failure

`Sep 2020 - Aug 2021`
**Postgraduate Representative**, *MedTech UCL*
- Chaired the UCL AI in Medicine conference, hosted speakers such as Eric Topol, Mihaela van der Schaar, and Manolis Kellis.

`Apr 2020 - Mar 2021`
**Chief Science Officer**, *MyGrow Design*
- Selected for the 2020 Pennovation Accelerator Cohort. Developed a bicycle helmet entirely biologically grown from mycelium-based foam.

`Aug 2017 - Mar 2020`
**Clinical Research**, *University of Pennsylvania*
- Studied the clinical effects of radiation treatment on chimeric antigen receptor T-cell (CAR T) Therapy.



## Publications

*Publication list also available [in Google Scholar](https://scholar.google.com/citations?user=Aab-TdsAAAAJ&hl=en). 


`2023`
SL Zheng, A Henry, D Cannie, M Lee, **D Miller**, KA McGurk, I Bond, X Xu, ... Genome-wide association analysis reveals insights into the molecular aetiology underlying dilated cardiomyopathy. *medRxiv*, 2023.09.28.23295408, 2023.

`2023`
A Henry, X Mo, C Finan, MD Chaffin, D Speed, H Issa, S Denaxas, **D Miller** ... Mapping the aetiological foundations of the heart failure spectrum using human genetics. *medRxiv*, 2023.10.01.23296379, 2023.

`2021`
N Vapiwala, **D Miller**, B Laventure, K Woodhouse, S Kelly, J Avelis, ... Stigma, beliefs and perceptions regarding prostate cancer among Black and Latino men and women. *BMC public health*, 21 (1), 1-11, 2021.

`2021`
YD Tseng, BS Hoppe, K Dedeckova, CG Patel, CE Hill-Kayser, **DM Miller**, ... Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. *International Journal of Radiation Oncology* Biology* Physics*, 109 (1), 220-230, 2021.

`2021`
JN Lukens, R Mick, ACC Huang, N Han, M Farwell, TC Mitchell, **D Miller** ... Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors. *Journal of Clinical Oncology*, 39 (15_suppl), 2576-2576, 2021.

`2020`
CM Wright, MJ LaRiviere, JA Baron, C Uche, Y Xiao, WT Arscott, **D Miller** ... Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma. *International Journal of Radiation Oncology* Biology* Physics*, 71, 2020.

`2020`
A Dreyfuss, M LaRiviere, J Mohiuddin, B Baumann, **D Miller**, S Mazzoni, ... A Phase I/II Clinical Trial of Proton Therapy for Chordomas and Chondrosarcomas: A091. *Journal of Neurological Surgery: Skull Base*, 81, 2020.

`2020`
AD Dreyfuss, MJ LaRiviere, JJ Mohiuddin, BC Baumann, **DM Miller**, ... A Phase I/II Clinical Trial of Proton Therapy for Chordomas and Chondrosarcomas. *Journal of Neurological Surgery Part B: Skull Base*, 81 (S 01), A091, 2020.

`2019`
MJ LaRiviere, CM Wright, WT Arscott, **D Miller**, E Weber, DJ Landsburg, ... Induction Radiation Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma. *International Journal of Radiation Oncology• Biology• Physics*, 105 (1), S66, 2019.

`2018`
WT Arscott, **D Miller**, JA Jones, N Winchell, S Schuster, JP Plastaras. Tandem Induction Radiation and Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. *International Journal of Radiation Oncology• Biology• Physics*, 102 (3), S122, 2018.

`2018`
JP Plastaras, A Maity, S Flampouri, **D Miller**, NP Mendenhall, J Svoboda, ... Bi-Institutional Report on Consolidative Proton Therapy after Initial Chemotherapy for Mediastinal Diffuse Large B-Cell and Primary Mediastinal Large B-Cell Lymphomas. *International Journal of Radiation Oncology• Biology• Physics*, 102 (3), e350, 2018.

`2017`
YD Tseng, BS Hoppe, **D Miller**, A Maity, RH Nanda, NP Mendenhall, ... Rates of Toxicity and Outcomes After Mediastinal Proton Therapy For Relapsed/Refractory Lymphoma. *International Journal of Radiation Oncology• Biology• Physics*, 99 (2), S62-S63, 2017.


## Teaching

`2022 – 2023`
**Computational Genetics of Healthcare**, *University College London*

## Honours and Awards

- International Scholar Award for Doctoral Training
- 4 Year MRC Doctoral Training Programme Studentship
- Distinction in MSc Thesis at University College London
- Global Scholar Award, Bright!Tax 2020
- W. Raymond Evans Memorial Prize in Mathematics
- Robert C. Porter Bowdoin-Penn Charter Scholarship







<br/>Last updated: May 2024<br/><br/>
